Medscape InDiscussion: CAR T-Cell Therapy Medscape

Join Drs Amelia Langston and Frederick Locke as they discuss the future of CAR T-cell therapy research and treatment.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987070). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Cancer Immunotherapy With Chimeric Antigen Receptor (CAR) T Cells https://emedicine.medscape.com/article/2500108-overview
Adoptive Cell Therapy https://www.cancer.gov/publications/dictionaries/cancer-terms/def/adoptive-cell-therapy
Graft Versus Host Disease (GVHD) https://emedicine.medscape.com/article/429037-overview
Multiple Myeloma https://emedicine.medscape.com/article/204369-overview
BCMA in Multiple Myeloma-A Promising Key to Therapy https://pubmed.ncbi.nlm.nih.gov/34575199/
Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on "Off-the-shelf" T Cell Therapy Using iPSC Technology and Gene Editing https://pubmed.ncbi.nlm.nih.gov/35053386/
Cytokine Release Syndrome https://emedicine.medscape.com/article/2500111-overview
Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/34466048/
Preclinical and Clinical Studies of CAR-NK-cell Therapies for Malignancies https://pubmed.ncbi.nlm.nih.gov/36353643/
How I Treat Cytopenias After CAR T-cell Therapy https://pubmed.ncbi.nlm.nih.gov/36800563/
T-cell Receptor-based Therapy: An Innovative Therapeutic Approach for Solid Tumors https://pubmed.ncbi.nlm.nih.gov/34193217/
Biochemistry, HLA Antigens https://www.ncbi.nlm.nih.gov/books/NBK546662/
CAR T-cell Cancer Therapy Targeting Surface Cancer/Testis Antigens https://pubmed.ncbi.nlm.nih.gov/32983080/
Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges https://pubmed.ncbi.nlm.nih.gov/36077696/
Axicabtagene Ciloleucel CAR T-cell Therapy in Refractory Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/29226797/
Axicabtagene Ciloleucel as Second-line Therapy for Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/34891224/

Join Drs Amelia Langston and Jonathan L. Kaufman, MD, as they discuss current CAR–T cell for B-cell lymphomas as leading researchers and practitioners in the field.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987069). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Cancer Immunotherapy With Chimeric Antigen Receptor (CAR) T Cells https://emedicine.medscape.com/article/2500108-overview
Multiple Myeloma https://emedicine.medscape.com/article/204369-overview
CD19 https://www.ncbi.nlm.nih.gov/gene/930
BCMA in Multiple Myeloma - A Promising Key to Therapy https://pubmed.ncbi.nlm.nih.gov/34575199/
Histology, Plasma Cells https://www.ncbi.nlm.nih.gov/books/NBK556082/
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/33626253/
Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b/2 Open-Label Study https://pubmed.ncbi.nlm.nih.gov/34175021/
Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life? [Internet] https://www.ncbi.nlm.nih.gov/books/NBK137763/
Ide-Cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/36762851/
Clinical Management of Triple-Class Refractory Multiple Myeloma: A Review of Current Strategies and Emerging Therapies https://pubmed.ncbi.nlm.nih.gov/35877215/
Bispecific Targeting of CD20 and CD19 Increases Polyfunctionality of Chimeric Antigen Receptor T-Cell Products in B-Cell Malignancies https://pubmed.ncbi.nlm.nih.gov/35597752/
Bridging Chemotherapy: Multiple Myeloma https://www.ncbi.nlm.nih.gov/books/NBK584176/
Autologous Bone Marrow Transplant https://www.cancer.gov/publications/dictionaries/cancer-terms/def/autologous-bone-marrow-transplant
Myelodysplastic Syndrome (MDS) https://emedicine.medscape.com/article/207347-overview
GPRC5D-Targeted CAR T Cells for Myeloma https://pubmed.ncbi.nlm.nih.gov/36170501/
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/36507686/
Elotuzumab: The First Approved Monoclonal Antibody for Multiple Myeloma Treatment https://pubmed.ncbi.nlm.nih.gov/27493709/
Natural Killer Cells in the Malignant Niche of Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/35087536/

Join Drs Amelia Langston and Loretta Nastoupil as they discuss current CAR T-cell therapy for B-cell lymphomas as leading researchers and practitioners in the field.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987068). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Axicabtagene Ciloleucel CAR T-cell Therapy in Refractory Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/29226797/
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/30501490/
Lisocabtagene Maraleucel for Patients With Relapsed or Refractory Large B-cell Lymphomas (TRANSCEND NHL 001): A Multicentre Seamless Design Study https://pubmed.ncbi.nlm.nih.gov/32888407/
Axicabtagene Ciloleucel as Second-line Therapy for Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/34891224/
Lisocabtagene Maraleucel Versus Standard of Care With Salvage Chemotherapy Followed by Autologous Stem Cell Transplantation as Second-line Treatment in Patients With Relapsed or Refractory Large B-cell Lymphoma (TRANSFORM): Results From an Interim Analysis of an Open-label, Randomised, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/35717989/
Second-line Tisagenlecleucel or Standard Care in Aggressive B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/34904798/
KTE-X19 CAR T-cell Therapy in Relapsed or Refractory Mantle-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/32242358/
Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5): A Single-arm, Multicentre, Phase 2 Trial https://pubmed.ncbi.nlm.nih.gov/34895487/
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (ZUMA-23) https://clinicaltrials.gov/ct2/show/NCT05605899
Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122857/

Join Drs Amelia Langston and Bijal Shah as they discuss CAR T-cell therapy for B-cell acute lymphoblastic leukemia, including clinical trials and real-world experience from their centers.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987067). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Cancer Immunotherapy With Chimeric Antigen Receptor (CAR) T Cells https://emedicine.medscape.com/article/2500108-overview
Acute Lymphoblastic Leukemia (ALL) Treatment & Management https://emedicine.medscape.com/article/207631-treatment#d15
Non-Hodgkin Lymphoma (NHL) https://emedicine.medscape.com/article/203399-overview
CD19 https://www.ncbi.nlm.nih.gov/gene/930
Tisagenlecleucel https://www.cancer.gov/publications/dictionaries/cancer-terms/def/tisagenlecleucel
Tisagenlecleucel in Children and Young Adults With B-Cell Lymphoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/29385370/
Clinical Significance and Management of MRD in Adults With Acute Lymphoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/32903253/
Blinatumomab (Rx) https://reference.medscape.com/drug/blincyto-blinatumomab-999984#10
FDA Approves Inotuzumab for Adults With B-Cell Acute Lymphoblastic Leukemia https://www.cancer.gov/news-events/cancer-currents-blog/2017/fda-inotuzumab-leukemia
Immune Effector Cell Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor-T Cell Therapy https://pubmed.ncbi.nlm.nih.gov/36081506/
Cytokine Release Syndrome https://emedicine.medscape.com/article/2500111-overview
Systemic Inflammatory Response Syndrome https://www.ncbi.nlm.nih.gov/books/NBK547669/
CD28 https://www.ncbi.nlm.nih.gov/gene/940
Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL) (ROCKET) https://clinicaltrials.gov/ct2/show/NCT02535364
KTE-X19 for Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukaemia: Phase 2 Results of the Single-Arm, Open-label, Multicentre ZUMA-3 Study https://pubmed.ncbi.nlm.nih.gov/34097852/
CAR T-Cell Therapy Approved for Some Children and Young Adults With Leukemia https://www.cancer.gov/news-events/cancer-currents-blog/2017/tisagenlecleucel-fda-childhood-leukemia
Allogeneic Stem Cell Transplant https://www.cancer.gov/publications/dictionaries/cancer-terms/def/allogeneic-stem-cell-transplant
clonoSEQ Assay https://ous.clonoseq.com/for-clinicians/how-clonoseq-works/
Management of Hypogammaglobulinaemia and B-Cell Aplasia https://www.ncbi.nlm.nih.gov/books/NBK584138/
Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse After Tisagenlecleucel in Children and Young Adults With Acute Lymphoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/35019853/
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial https://pubmed.ncbi.nlm.nih.gov/36399695/
Therapeutic Targeting of Mutated p53 in Acute Lymphoblastic Leukemia https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939537/
MLL-Rearranged Acute Lymphoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/32350732/
Liposomal Vincristine for Relapsed or Refractory Ph-Negative Acute Lymphoblastic Leukemia: A Review of Literature https://pubmed.ncbi.nlm.nih.gov/24490021/
Consolidation Therapy With Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients With B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results From the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial https://ashpublications.org/blood/article/140/Supplement%202/LBA-1/493429/Consolidation-Therapy-with-Blinatumomab-Improves

Join Drs Amelia Langston and Jean Koff as they discuss the monitoring and management of complications before, during, and after CAR T therapy.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987066). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Cancer Immunotherapy With Chimeric Antigen Receptor (CAR) T Cells https://emedicine.medscape.com/article/2500108-overview
Cytokine Release Syndrome https://emedicine.medscape.com/article/2500111-overview
Immune Effector Cell Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor-T Cell Therapy https://pubmed.ncbi.nlm.nih.gov/36081506/
On-target and Off-target-based Toxicologic Effects https://pubmed.ncbi.nlm.nih.gov/23085982/
Cytokine https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cytokine
Tocilizumab (Rx) https://reference.medscape.com/drug/actemra-tocilizumab-999419
CARTOX 10 Point Neurological Assessment https://reference.medscape.com/viewarticle/886616_5
Levetiracetam https://www.ncbi.nlm.nih.gov/books/NBK499890/
Cytopenia After CAR-T Cell Therapy-A Brief Review of a Complex Problem https://pubmed.ncbi.nlm.nih.gov/35326654/
Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome https://pubmed.ncbi.nlm.nih.gov/36906275/
Management of Hypogammaglobulinaemia and B-cell Aplasia https://www.ncbi.nlm.nih.gov/books/NBK584138/
Rituximab (Rx) https://reference.medscape.com/drug/rituxan-truxima-rituximab-342243
Bispecific Targeting of CD20 and CD19 Increases Polyfunctionality of Chimeric Antigen Receptor T-cell Products in B-cell Malignancies https://pubmed.ncbi.nlm.nih.gov/35597752/
Mantle Cell Lymphoma https://www.ncbi.nlm.nih.gov/books/NBK536985/
Chimeric Antigen Receptor (CAR) T-cell Treatment for Mantle Cell Lymphoma (MCL) https://pubmed.ncbi.nlm.nih.gov/35237395/
Apheresis https://www.cancer.gov/publications/dictionaries/cancer-terms/def/apheresis

Drs Amelia Langston and Melody Smith provide an overview of CAR T-cell therapy, the products available, potential complications, and what's next in this rapidly advancing field.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987065). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Non-viral, Specifically Targeted CAR-T Cells Achieve High Safety and Efficacy in B-NHL https://pubmed.ncbi.nlm.nih.gov/36045296/
Cytokine Release Syndrome With Chimeric Antigen Receptor T Cell Therapy https://pubmed.ncbi.nlm.nih.gov/30586620/
Immune Effector Cell-Associated Neurotoxicity Syndrome After Chimeric Antigen Receptor T-Cell Therapy for Lymphoma: Predictive Biomarkers and Clinical Outcomes https://pubmed.ncbi.nlm.nih.gov/32750704/
A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/33670075/
CAR T-cell Therapy for B-Cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/35012754/
Current State and Next-Generation CAR-T Cells in Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/35131139/
Rapid Manufacturing of Non-activated Potent CAR T Cells https://pubmed.ncbi.nlm.nih.gov/35190680/